INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer's Disease to npj Dementia, a Nature Portfolio Journal GlobeNewswire September 29, 2025 Boca Raton, FL, Sept. 29, 2025 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces the submission of a manuscript detailing the results of […]